Victor Cervera-Carrascon | Head Of Immunology
TILT Biotherapeutics

Victor Cervera-Carrascon, Head Of Immunology, TILT Biotherapeutics

Head of Immunology, Víctor Cervera-Carrascón, has expertise in immunotherapy, particularly on the use of oncolytic viruses to enable immune checkpoint blockade and other T-cell related approaches. Víctor obtained a PhD in a Marie Skłodowska-Curie consortium (The Netherlands and Finland) in oncolytic viruses. Víctor is responsible for the planning and management of correlative analyses related to TILT’s clinical trials and supporting the translation of preclinical success into the clinical arena, as well as supporting business development activities

Appearances:



Festival of Biologics Day 1 @ 17:30

Development of a T-cell centred oncolytic virus against solid tumors

  • TILT-123 is an oncolytic adenovirus developed after a number or optimization rounds to achieve best inclass Pharmacokinetic and Pharmacodynamic properties.
  • Conclusions from human data were taken back to the lab for validation and showed the promise of use of TILT-123 to enable immune checkpoint inhibitors, CAR T-cell therapy and ACT-TIL therapy.
  • Clinical development is ongoing where the use of TILT-123 with different T-cell therapies is being studied for different solidtumorindications.
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT

back to speakers